Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey, Clay. Chart for $STHC please, if you get a chance?!
Thanks so much and Happy Holidays!
Yep! I was here when we were in dollar land. I just notified my investor buddies as well. This board has always been quiet.
GLTU!
$GBLX
GB Sciences Announces Issuance of US Patent for its Proprietary, Cannabinoid-Based Anti-Inflammatory Formulations
10:05 AM ET 12/8/20 | Dow Jones
LAS VEGAS, NV / ACCESSWIRE / December 8, 2020 / GB Sciences, Inc. (OTCQB:GBLX) announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent No. 10,857,107 entitled "Cannabinoid-Containing Complex Mixtures for the Treatment of Mast-Cell-Associated or Basophil-Mediated Inflammatory Disorders" today, Dec. 8, 2020. This U.S. patent is assigned to GBS Global Biopharma (GBS), Inc., GB Sciences' Canadian entity. GBS's new U.S. patent protects methods of using GBS's proprietary cannabinoid-containing complex mixtures (CCCM(TM)) for treating Mast Cell Activation Syndrome (MCAS). MCAS is a severe immunological condition in which mast cells inappropriately and excessively release inflammatory mediators, resulting in a range of severe chronic hyperinflammatory symptoms and life-threatening anaphylaxis attacks.
"Receiving our patent for the treatment of MCAS using GBS's CCCM(TM) is an important milestone in the development of this urgently needed medicine. There is no single recommended treatment for MCAS patients. Instead, they attempt to manage MCAS symptoms primarily by avoiding 'triggers' and using rescue medicines for their severe hyperinflammatory attacks. Therefore, MCAS patients need new therapeutic options to control their mast cell related symptoms, and our CCCM(TM) were designed to simultaneously control multiple inflammatory pathways within mast cells as a comprehensive treatment option," explained Dr. Andrea Small-Howard, Chief Science Officer and Director of both GB Sciences, Inc. and GBS Global Biopharma, Inc. "Our company is strategically targeting MCAS for two additional reasons. By focusing on a rare disease with no known cure, our company can apply for the U.S. Food and Drug Administration's expedited approval process, which allows clinically successful treatments to get to market both quicker and more cost-effectively. Gaining approval from the U.S. FDA for the entire anti-inflammatory market would be extremely time-consuming and cost-prohibitive. Demonstrating that our CCCM(TM) are safe for the treatment of MCAS would favorably position our Company for clinical testing of these CCCM(TM) as potential treatments for other related inflammatory disorders, such as inflammatory bowel disease, thereby widening the target market and drastically shortening the development cycle and costs."
GBS's intellectual property portfolio contains multiple patent families covering different CCCM(TM) containing novel combinations of active pharmaceutical ingredients that are complex mixtures composed of natural or synthetic homologs of cannabis-derived ingredients. In addition to the U.S. patent issued for its MCAS CCCM(TM), GBS's intellectual property portfolio currently contains four patents that are issued in the U.S. with corresponding patents issued internationally. Seven nonprovisional patent applications and three provisional patent applications are pending in the U.S. and 29 patent applications have been filed internationally drawn to CCCM(TM) for the treatment of neuropathic pain, inflammatory disorders, cardiovascular disease, neurodegenerative conditions and a variety of other clinically unmet needs.
"Our focus on this rare disease offers strategic advantages in development and entry into the lucrative anti-inflammatory market," said John Poss, CEO and Chairman of GB Sciences, Inc. "This U.S. patent further validates our drug discovery platform and strengthens our intellectual property portfolio of unique CCCM(TM), each targeting one of up to 50 specific clinical applications."
About GB Sciences, Inc. and GBS Global Biopharma, Inc.
GB Sciences, Inc. (OTCQB:GBLX), through its Canadian entity GBS Global Biopharma, Inc., is a dedicated biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets.
Bought the dip twice today! Thanks for the cheapies.
Looking good. Added more today.
Batter up! Sorry, was watching my other runners. Looks Like somethings cooking here. $MLHC
Eventually they all run due to MOMO or facts, just have to be patient and also do your DD. GLTUA
When one sister moves, the other does! It's coming.
Welcome and good move! $RSHN! Just getting started
I sold but I might get back in. Lots of trips moving now.
Could take a year and that's ok. We are going through a Pandemic! Unchartered territories. In the interim, we ride the waves and lots of things are happening in the background while we wait...
$GRPS
Patience is a virtue! I have all the time in the world.
$GRPS $R$HN
Hello!
I second , third that!
Thanks, but there are bigger turds out there. Churning, churning!
GLTU
Nice! Let's get the party started right! $RSHN $GRP$
Nice job! I'd be happy with 0008s, too. VWAP so far is .000867
Got a couple orders in. Hopefully someone rocks this boat again
I hope so! Please sell them to me. Adding here.
Nice, screen shot?!
Come back, still going to run. Find an entry!
$RSHN
Bid x size
0.0004 x 92,471,389
Ask x size
0.0005 x 5,006,512
WHAT?!?!
RSI still looking good. Plenty of room to keep running.
$RSHN get in now while cheap.
This once ran every week for two months, remember? Still same AS/OS so can do the same or better now!
Whoohooo $RSHN
MLHC is sister I am in as well. GLTU
Whooo! Lets go $RSHN
Maui to the moon!
I've been in both for a while. Nice to see some action on both. Best of luck to us all.
sister starting to run. Silent loaders at .0001
$WWIO
Yeah, sister running too WWIO 900 million +
$MLCH $WWIO
Yeah, let's Air BnB a huge house on the beach and celebrate!
Happy Thanksgiving, $RSHN
Thanks, JJ. Been here for a while, just haven't posted.
$BFCH
Outstanding Shares
219,145,701
11/23/2020
https://www.otcmarkets.com/stock/BFCH/security
So what? That's not bad for pinkies. I've seen much worse run. Also, RSHN ran before with this SS and they have not diluted it or increased SS since then.
$RSHN $GRPS
BID $0.0003 x 60,284,500
ASK $0.0004 x 555,600
Do the math!
RSHN
Per Doc, GRPS should be current by tomorrow.
NO RS. The RS was Stop Drops idea and when the deal fell through the RS was not needed. RSHN is still working with Stop Drops on other initiatives, however.
Watch the video on FB. Answering lots of Qs.